(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of -15.26% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Scynexis's revenue in 2024 is $140,141,000.On average, 1 Wall Street analysts forecast SCYX's revenue for 2024 to be $421,328,848, with the lowest SCYX revenue forecast at $421,328,848, and the highest SCYX revenue forecast at $421,328,848. On average, 1 Wall Street analysts forecast SCYX's revenue for 2025 to be $1,811,034,484, with the lowest SCYX revenue forecast at $1,811,034,484, and the highest SCYX revenue forecast at $1,811,034,484.
In 2026, SCYX is forecast to generate $3,223,769,743 in revenue, with the lowest revenue forecast at $3,223,769,743 and the highest revenue forecast at $3,223,769,743.